Strata Critical Medical, Inc. (SRTA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Strata Critical Medical, Inc. operates as a national provider of time-critical logistics and medical services, primarily serving the U.S. healthcare industry with air/ground transport and surgical services for organ transplants. The company operates two segments: Logistics and Clinical. Notable strategic shifts include the completed sale of its Passenger business (classified as discontinued operations) in August 2025 and the acquisition of Keystone Perfusion Services in September 2025, alongside three smaller clinical acquisitions in Q2 2026.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $72,506 | $45,108 | $139,890 | $81,056 |
| Gross Profit | $15,215 | $9,007 | $29,332 | $16,060 |
| Gross Margin | 21.0% | 20.0% | 21.0% | 19.8% |
| Operating Loss | $(5,408) | $(4,641) | $(8,382) | $(10,326) |
| Net Loss (Continuing Ops) | $(10,516) | $(3,409) | $(8,114) | $(5,021) |
| Net Loss (Total) | $(10,516) | $(3,743) | $(8,362) | $(7,236) |
| Adjusted EBITDA | $7,887 | $2,466 | $14,297 | $2,882 |
| Cash & Equivalents | $16,317 | $58,754 | $16,317 | $58,754 |
| Short-term Investments | $6,436 | $30,263 | $6,436 | $30,263 |
| Total Liquidity | $22,753 | $89,017 | $22,753 | $89,017 |
Note: Total Liquidity includes Cash, Cash Equivalents, and Short-term Investments. Restricted cash of $264k is excluded from the liquidity total above but included in total cash balances.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 60.7% QoQ and 72.6% YTD, driven by the inclusion of the Clinical segment (Keystone acquisition) and growth in Logistics revenue per flight hour.
- Amortization Spike: Amortization of intangible assets surged to $6.6M in Q2 2026 (from $0.4M in Q2 2025) due to accelerated amortization of trade names for rebranding and new intangibles from acquisitions.
- Non-Operating Loss: A $5.5M non-cash loss in Q2 2026 resulted from the remeasurement of fair value for assets and liabilities (contingent consideration), contrasting with non-operating income in the prior year.
- Cash Position: Cash and short-term investments decreased significantly from $89.0M at year-end 2025 to $22.8M at June 30, 2026, primarily due to $34.8M in cash consideration paid for 2026 acquisitions and capital expenditures.
- Warrant Liability: Public and Private warrants expired unexercised in May 2026, eliminating the associated liability and fair value volatility.
Guidance, Outlook, and Risks
Management Commentary: Management highlights that the company has sufficient liquidity ($22.8M) to meet operational needs for the next 12 months. The company entered a $30M asset-based revolving credit facility (ABL) in January 2026, which remains undrawn. Adjusted EBITDA improved significantly to $7.9M in Q2 2026, reflecting the profitability of the Clinical segment.
Risks and Contingencies:
- Contingent Consideration: Significant fair value adjustments related to earn-outs for the Keystone and LPS acquisitions impact net income volatility.
- Discontinued Operations: The company retains contingent assets from the Passenger business sale (Joby Aviation) totaling ~$40.8M, subject to performance targets.
- Operational Risks: Dependence on donor organ volumes, third-party aircraft capacity, and clinician retention.
- Rebranding Costs: Accelerated amortization of trade names will continue through September 2026 as the company unifies under the Strata brand.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and margin profile of the 2026 acquisitions (OVPA, LPS, HLT-NRP) and the Keystone integration.
- Liquidity Runway: Confirm the burn rate given the drop in cash reserves from $89M to $22.8M and the reliance on the undrawn $30M credit facility.
- Non-GAAP Reconciliation: Scrutinize the Adjusted EBITDA reconciliation, specifically the $5.5M fair value adjustment and $5.0M accelerated amortization excluded from the metric.
- Contingent Assets/Liabilities: Monitor the fair value changes of the Joby Aviation earn-out assets and the Keystone/LPS earn-out liabilities.
- Warrant Expiration: Confirm no residual liability remains from the May 2026 warrant expiration.